X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The financing will enable the company to support Ji Xing Pharmaceuticals in the commercialization of JIXING’s pipeline assets in the areas of cardiovascular diseases and ophthalmology.
Lead Product(s): Aficamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CK-3773274
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: $162.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing January 06, 2024
Details:
CK-3773274 (aficamten) is an investigational selective, small molecule cardiac myosin inhibitor. It is under phase 3 clinical development fot the treatment of obstructive hypertrophic cardiomyopathy.
Lead Product(s): Aficamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CK-3773274
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 27, 2023
Details:
CK-274 (aficamten), is small molecule cardiac myosin inhibitor discovered following an extensive chemical optimization program, which is investigated for Symptomatic Obstructive Hypertrophic Cardiomyopathy.
Lead Product(s): Aficamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CK-274
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2023
Details:
CK-274 (aficamten), is small molecule cardiac myosin inhibitor discovered following an extensive chemical optimization program, which is investigated for Symptomatic Obstructive Hypertrophic Cardiomyopathy.
Lead Product(s): Aficamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CK-3773274
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
Details:
Data from REDWOOD-HCM showed that treatment with CK-274 (aficamten), investigational selective, small molecule cardiac myosin inhibitor was associated with significant and sustained reduction in LVOT-G improvement in NYHA Functional Class and improvement in cardiac biomarker.
Lead Product(s): Aficamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CK-274
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2022
Details:
CK-274 (aficamten) is a novel, oral, small molecule cardiac myosin inhibitor. CK-274 is designed to reduce the number of active actin-myosin cross bridges during each cardiac cycle and consequently reduce myocardial contractility.
Lead Product(s): Aficamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CK-274
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2022
Details:
Aficamten (CK-274), is small molecule cardiac myosin inhibitor discovered following an extensive chemical optimization program that was conducted with careful attention to therapeutic index and pharmacokinetic properties and translate into clinical development.
Lead Product(s): Aficamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CK-274
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2022
Details:
The new analysis investigated changes from baseline in echocardiographic measures of cardiac structure and function after 10 weeks of treatment with aficamten (CK-274) compared with placebo.
Lead Product(s): Aficamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CK-274
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2022
Details:
Data showed that treatment with CK-274 (aficamten) was associated with substantial reductions in the average resting LVOT-G = -32.6 mmHg, p<0.0001 at 12 weeks, -32.8 mmHg, p=0.0003 at 24 weeks, and Valsalva LVOT-G mmHg, p<0.0001 at 12 weeks.
Lead Product(s): Aficamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CK-274
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2022
Details:
Treatment with aficamten resulted in 6 of the 13 patients (46%) experiencing complete hemodynamic response by Week 10, with remaining 7 (54%) still eligible for dose escalation to the highest dose of aficamten (20 mg) employed in SEQUOIA-HCM, the Phase 3 trial.
Lead Product(s): Aficamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CK-274
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2022
Details:
Cohort 4 of REDWOOD-HCM an ongoing trial of CK-274 (aficamten), an investigational next-generation cardiac myosin inhibitor in development for the potential treatment of hypertrophic cardiomyopathy, will enroll patients with non-obstructive hypertrophic cardiomyopathy.
Lead Product(s): Aficamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CK-274
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2022
Details:
Results from Cohorts 1 and 2 of REDWOOD-HCM demonstrated that treatment with CK-274 for 10 weeks resulted in statistically significant reductions from baseline compared to placebo in the average resting left ventricular outflow tract pressure gradient.
Lead Product(s): Aficamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CK-274
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2021
Details:
Cytokinetics is developing CK-274, a next-generation cardiac myosin inhibitor, for the potential treatment of hypertrophic cardiomyopathies (HCM). Cytokinetics is conducting REDWOOD-HCM, a Phase 2 clinical trial of CK-274 in patients with obstructive HCM.
Lead Product(s): Aficamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CK-274
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2021
Details:
First patient has been dosed in Cohort 2 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), an ongoing Phase 2 clinical trial of CK-3773274 (CK-274). This event triggers a $2.5 million milestone payment.
Lead Product(s): Aficamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CK-274
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ji Xing Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2021
Details:
U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CK-3773274 (CK-274) for the treatment of symptomatic hypertrophic cardiomyopathy (HCM). CK-274 is a next-generation cardiac myosin inhibitor in development for the potential treatment of HCM.
Lead Product(s): Aficamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CK-274
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2021
Details:
CK-274 reduced contractility and left ventricular outflow tract (LVOT) peak pressure gradient in cats with naturally occurring hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract obstruction (LVOTO).
Lead Product(s): Aficamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CK-274
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ji Xing Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
Details:
Cytokinetics has agreed to a series of transactions with certain companies wholly owned by investment funds managed by RTW Investments, LP, and Ji Xing Pharmaceuticals Limited related to CK-3773274.
Lead Product(s): Aficamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CK-274
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: RTW Investments
Deal Size: $450.0 million Upfront Cash: Undisclosed
Deal Type: Financing July 14, 2020
Details:
Preclinical studies demonstrate distinct binding site for Next-Generation Cardiac Myosin Inhibitor.
Lead Product(s): Aficamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2020
Details:
REDWOOD-HCM is a Phase 2 clinical trial of CK-3773274 (CK-274), a next-generation cardiac myosin inhibitor discovered by company scientists, which Cytokinetics is developing for the potential treatment of (HCM).
Lead Product(s): Aficamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
